Cargando…
PMON69 Effective Suppression of Gonadotropins and Gonadal Steroids Following Oral Administration of Leuprolide
A platform designed to enable systemic delivery of peptides via the oral-GI route was employed to deliver low doses of leuprolide --- 4 mg qd (Treatment A, n=9), 4 mg bid (Treatment B, n=9), and 10 mg bid (Treatment D, n=12) --- daily for 28 days to regularly-menstruating, healthy female volunteers....
Autores principales: | Shangold, Gary, Rubin, Arkady, Daggs, Thomas, Vrettos, John, Rasums, Andrejs, Consalvo, Angelo, Skeet, Nicola, Shields, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625566/ http://dx.doi.org/10.1210/jendso/bvac150.1165 |
Ejemplares similares
-
PMON70 Systemic Delivery of Leuprolide via Oral Administration
por: Shangold, Gary, et al.
Publicado: (2022) -
PMON91 Late Presentation of Pituitary Apoplexy Following Gonadotropin-Releasing Hormone Agonist for Prostate Cancer Treatment
por: Raj, Rishi, et al.
Publicado: (2022) -
SUN-421 Leuprolide Injection Induced Pituitary Apoplexy
por: Jaggi, Shirin, et al.
Publicado: (2019) -
PMON75 Unilateral Galactorrhea in an Elderly Male
por: Monsour, Elio, et al.
Publicado: (2022) -
PMON112 Primary Pituitary Lymphoma Presenting as Apoplexy
por: Abdelaziz, Sara, et al.
Publicado: (2022)